

EXUDATE MANAGEMENT PATHWAY



Nil to Low



Moist



Moderate



Saturated



KERRALITE COOL™ DRESSINGS

Soothing hydrogel sheet dressings

- Effective debridement of devitalised tissue¹
- Reduced risk of maceration²
- Excellent fluid management properties²
- A significant reduction in pain²

KERRACEL™ DRESSINGS

Gelling fibrous dressing

- Forms a soothing gel when wet
- Helps maintain a moist wound environment
- Locks in exudate to protect peri wound skin from maceration³

KERRAFOAM™ GENTLE BORDER DRESSING

Conformable silicone adhesive bordered dressing

- Unique wicking layer distributes exudate throughout the dressing evenly
- EXUSAFE™ Technology protects patients:
 - Peri wound skin from maceration⁴
 - Locks away bacteria and MMP's that could be harmful⁵

KERRAFOAM™ SIMPLE DRESSINGS

Conformable silicone adhesive bordered and non-bordered dressing


- Absorbs and retains exudate⁶
- Protects the wound from external contamination by providing a bacteria and waterproof barrier

KERRAMAX CARE™ DRESSINGS

Superabsorbent dressing

- High absorbency and retention⁷
- EXUSAFE™ Technology – Protects patients by locking away potentially harmful bacteria and MMP's⁸
- Unique wicking layer distributes exudate throughout the dressing evenly
- Highly conformable allowing the dressing to be folded for variety of different wounds

CONSIDER OTHER PRIORITIES:



Delicate Skin

ADAPTIC TOUCH™ DRESSING

Silicone wound contact layer dressing

- Primary dressing wound contact dressing
- Protects the patient by minimising pain and trauma at dressing removal¹⁰

Odour

ACTISORB™ SILVER 220 DRESSING

Activated charcoal and silver dressing

- The dressing traps odour in the dressing and binds bacteria and toxins that impair the healing process^{11*}
- Silver kills the bacteria in the dressing^{11*}

Infection

PLEASE REFER TO: INFECTION PATHWAY

Has the wound stalled?

PROMOGRAN™ MATRIX

Collagen/ORC primary wound dressing

Wounds not infected with delayed healing and without overt signs of infection:

- Reduces inflammatory markers and stimulates granulation tissue¹³
- Binds excess inflammatory proteases, protects growth factors and lowers pH¹⁴
- Clinically proven to shorten a patients stay in hospital¹⁵
- Significantly reduces wound size¹⁵

* When compared against standard care.

PROMOGRAN PRISMA™ MATRIX

Silver/Collagen/ORC primary wound dressing

Wounds at risk of infection:

- Reduces inflammatory markers and stimulates granulation tissue¹³
- Binds excess inflammatory proteases, protects growth factors and lowers pH¹⁴
- Kills bacteria in biofilms^{16*}
- Reduces bacterial proteases^{14*}
- Better healing and faster time to granulation than other collagen dressings¹⁷

Specific indications, contraindications, warnings, precautions and safety information may exist for Systagenix, Crawford and KCI (Acelyty companies) products. Please consult a healthcare provider and product instructions for use prior to application. This material is intended for healthcare professionals.

References: 1. Williams-Kelly W. Kerralite Cool for the debridement of a painful leg ulcer. Poster presented at: Wounds UK Annual Conference; November 13-15, 2017; Harrogate, UK. 2. Irvin N. Evaluation of the mode of action of a new gel wound dressing. Wounds UK. 2014;10(2). 3. Abaka-Wood R. A series to analyse KerraCel, Aquacel Extra and Durafiber samples - R6D Trial report CHC R189 (in vitro). Knutsford, UK: Crawford Healthcare; 2014. 4. Stephenson Cet al. A fluid retention assessment of KerraFoam Gentle Border & competitor products. Poster presented at: Wounds UK Annual Conference; November 10-12, 2014; Harrogate, UK. 5. Perfectus Biomed. Crawford 006 Final Report V1.5. Knutsford, UK: Crawford Healthcare; 2015. 6. Byrne C. Lab performance evaluation of silicone adhesive foam suppliers (bordered and non-bordered) - R6D Trial report CHC R614. Knutsford, UK: Crawford Healthcare; 2017. 7. Lovett J A summary report of the absorbency, retention, fluid wicking and conformability of Kerramax Care R6D Trial report CHC R669. Knutsford, UK: Crawford Healthcare; 2018. 8. Abaka-Wood R. A Product comparison portfolio for KerraFoamTM Gentle Border. R6D Trial report CHC R186. Knutsford, UK: Crawford Healthcare; 2015. 9. Thomas H, Westgate SJ. An in vitro comparison of MRSA and P. aeruginosa sequestration by five superabsorbent wound dressings. Poster presented at: Wounds UK Annual Conference; November 9-11, 2015; Harrogate, UK. 10. International case series: Using Adaptic Touch™ non-adhering silicone dressing: case studies. Wounds International. London; 2013. 11. Rennison, et al. Antimicrobial efficacy of silver impregnated activated charcoal wound dressing. Poster presented at: ETRS; September 21-23, 2003; Amsterdam, NL. 12. Young T. The challenge of managing fungating wounds. Journal of Wound Care. 18(7):232-234. 13. Gibson D, Cullen B, Legerstee R, Harding KG, Schultz G. MMPs Made Easy. Wounds International 2009; Feb 1. 14. Holmes C, Wrobel J, MacEachern M, Boles B. Collagen-based wound dressings for the treatment of diabetes-related foot ulcers: a systematic review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013; 6:17-29. 15. Vin F, et al. The healing properties of Promogran in venous leg ulcers. Journal of Wound Care. 2002; 11(9):335-41. 16. In vitro data - Bourdillon K, Delury C and Cullen B. Biofilms and delayed healing – an in vitro evaluation of silver- and iodine-containing dressings and their effect on bacterial and human cells. International Wound Journal. 2017; doi:10.1111/iwj.12761. 17. KCI Comparative Effectiveness of PROMOGRAN PRISMA™ Matrix vs Endoform™ Dermal Template. April 2018.

Copyright 2019 KCI Licensing, Inc. All rights reserved. Unless otherwise noted, all trademarks designated herein are proprietary to KCI Licensing, Inc., Systagenix Wound Management, Ltd., or Crawford Healthcare, Ltd. PRA-PM-EU-00173(05/19)